Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAZEBO trial in early-stage follicular lymphoma
2022-502775-29-01Phase 3Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2022-502775-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502775-29-01.